MCID: ORL007
MIFTS: 57

Oral Cavity Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oral Cavity Cancer

MalaCards integrated aliases for Oral Cavity Cancer:

Name: Oral Cavity Cancer 12 15 17
Malignant Neoplasm of Floor of Mouth 12 32
Malignant Neoplasm of Anterior Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Floor of Mouth 12
Malignant Tumor of Anterior Floor of Mouth 12
Malignant Tumor of Lateral Floor of Mouth 12
Malignant Tumor of the Floor of the Mouth 12
Malignant Tumor of Floor of Mouth 6
Malignant Neoplasm of Mouth 71
Oral Cavity Carcinoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8618
NCIt 49 C9318
UMLS 71 C0151546 C0153368 C0153369 more

Summaries for Oral Cavity Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of floor of mouth, is related to salivary gland carcinoma and oral cancer. An important gene associated with Oral Cavity Cancer is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include the, lymph node and tongue, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Decreased viability with paclitaxel

Related Diseases for Oral Cavity Cancer

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 223)
# Related Disease Score Top Affiliating Genes
1 salivary gland carcinoma 33.2 SOX2 GSTM1 ERBB2 EGFR
2 oral cancer 32.3 GSTM1 EGFR CYP1A1
3 oropharynx cancer 31.8 VEGFA PTEN PIK3CA ERBB2 EGFR
4 squamous cell carcinoma 31.8 VEGFA TNFRSF10B PTEN PIK3CA ERBB2 EGFR
5 papilloma 31.6 VEGFA PTEN IL4 EGFR
6 obsolete: squamous cell carcinoma of head and neck 31.4 TNFRSF10B PTEN PIK3CA EGFR
7 adenoid cystic carcinoma 31.3 VEGFA SOX2 PTEN PIK3CA ERBB2 EGFR
8 tongue squamous cell carcinoma 31.2 VEGFA SOX2 PTEN EGFR
9 esophageal cancer 31.1 VEGFA SOX2 PTEN PIK3CA GSTM1 ERCC1
10 nasopharyngeal carcinoma 30.9 VEGFA SOX2 PTEN PIK3CA GSTM1 ERBB2
11 squamous cell carcinoma, head and neck 30.9 VEGFA TNFRSF10B PTEN PIK3CA MCL1 GSTM1
12 lymphoma, non-hodgkin, familial 30.9 VEGFA TNFRSF10B SOD2 PTEN PIK3CA MCL1
13 melanoma 30.8 VEGFA TNFRSF10B PTEN PIK3CA ERBB2 EGFR
14 endocarditis 30.6 TLR6 TLR2 CAT
15 lip and oral cavity cancer 12.6
16 oral squamous cell carcinoma 11.6
17 primary peritoneal carcinoma 10.9 VEGFA ERCC1 ERBB2 EGFR
18 gastroesophageal junction adenocarcinoma 10.9 VEGFA ERBB2 EGFR
19 placental site trophoblastic tumor 10.9 VEGFA ERBB2 EGFR
20 toxic oil syndrome 10.9 IL4 GSTM1 CYP1A1
21 cystadenocarcinoma 10.9 VEGFA PIK3CA ERBB2
22 hair disease 10.9 VEGFA IL4 ERBB2 EGFR
23 gliosarcoma 10.9 VEGFA SOX2 PTEN ERBB2 EGFR
24 hypersensitivity reaction type iv disease 10.9 TLR2 IL4 FADD CASP8
25 pneumoconiosis 10.9 IL4 GSTM1 CAT CASP8
26 autonomic nervous system neoplasm 10.9 VEGFA PTEN ERBB2 EGFR CASP8
27 endometrial adenocarcinoma 10.9 VEGFA PTEN ERBB2 EGFR
28 peripheral nervous system neoplasm 10.9 VEGFA PTEN ERBB2 EGFR CASP8
29 estrogen-receptor positive breast cancer 10.9 VEGFA PIK3CA ERBB2 EGFR
30 vulvar disease 10.9 PIK3CA ERBB2 EGFR
31 breast carcinoma in situ 10.9 VEGFA PTEN ERBB2 EGFR
32 gastroesophageal adenocarcinoma 10.9 PTEN GSTM1 ERCC1 ERBB2 EGFR
33 malignant glioma 10.9 VEGFA TNFRSF10B PTEN EGFR CASP8
34 bile duct adenocarcinoma 10.9 VEGFA PTEN ERBB2 EGFR
35 cervical squamous cell carcinoma 10.8 VEGFA SOX2 PIK3CA EGFR
36 breast disease 10.8 VEGFA SOD2 ERBB2 CYP1A1 CAT
37 adenocarcinoma 10.8 VEGFA PTEN PIK3CA ERBB2 EGFR
38 ewing sarcoma 10.8 VEGFA SOX2 ERBB2 EGFR CASP8
39 uterine body mixed cancer 10.8 PTEN PIK3CA ERBB2 EGFR
40 gastrointestinal stromal tumor 10.8 VEGFA PTEN MCL1 ERBB2 EGFR CASP8
41 bronchitis 10.8 VEGFA TLR2 IL4 CAT
42 pre-malignant neoplasm 10.8 VEGFA PTEN PIK3CA ERBB2 EGFR
43 breast adenocarcinoma 10.8 SOD2 PIK3CA FADD ERBB2 EGFR CYP1A1
44 carcinosarcoma 10.8 PTEN PIK3CA ERBB2 EGFR
45 mixed cell type cancer 10.8 PTEN PIK3CA ERBB2 EGFR
46 ovary adenocarcinoma 10.8 VEGFA PTEN PIK3CA ERBB2 EGFR
47 serous cystadenocarcinoma 10.8 VEGFA PTEN PIK3CA ERBB2
48 ductal carcinoma in situ 10.8 VEGFA PTEN PIK3CA ERBB2 EGFR
49 mycoplasma pneumoniae pneumonia 10.8 TLR2 IL4 CYP1A1
50 primary bacterial infectious disease 10.8 TLR6 TLR2 IL4 CAT

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:



Diseases related to Oral Cavity Cancer

Symptoms & Phenotypes for Oral Cavity Cancer

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 EGFR ERBB2 GSTM1 PTEN VEGFA
2 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 FADD
3 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Oral Cavity Cancer:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 CASP8 CAT EDNRB EGFR ERBB2 ERCC1
2 homeostasis/metabolism MP:0005376 10.45 CASP8 CAT CYP1A1 EDNRB EGFR ERBB2
3 growth/size/body region MP:0005378 10.44 CASP8 CYP1A1 EDNRB EGFR ERBB2 ERCC1
4 endocrine/exocrine gland MP:0005379 10.42 CASP8 CYP1A1 EDNRB EGFR ERBB2 ERCC1
5 mortality/aging MP:0010768 10.42 CASP8 CAT CYP1A1 EDNRB EGFR ERBB2
6 immune system MP:0005387 10.41 CASP8 CYP1A1 EDNRB EGFR ERCC1 FADD
7 hematopoietic system MP:0005397 10.4 CASP8 CYP1A1 EDNRB EGFR ERCC1 FADD
8 cardiovascular system MP:0005385 10.38 CASP8 CYP1A1 EDNRB EGFR ERBB2 FADD
9 integument MP:0010771 10.34 CASP8 EDNRB EGFR ERBB2 ERCC1 IL4
10 embryo MP:0005380 10.32 CASP8 EDNRB EGFR ERBB2 ERCC1 FADD
11 muscle MP:0005369 10.26 CASP8 EDNRB EGFR ERBB2 ERCC1 FADD
12 liver/biliary system MP:0005370 10.25 CASP8 CYP1A1 EGFR ERCC1 FADD GDF15
13 nervous system MP:0003631 10.25 CASP8 EDNRB EGFR ERBB2 FADD GDF15
14 digestive/alimentary MP:0005381 10.24 EDNRB EGFR ERBB2 FADD IL4 PTEN
15 neoplasm MP:0002006 10.23 CASP8 CAT EDNRB EGFR ERBB2 ERCC1
16 adipose tissue MP:0005375 10.16 EGFR ERCC1 GDF15 PIK3CA PTEN SOD2
17 normal MP:0002873 10.02 CYP1A1 EGFR ERBB2 IL4 MCL1 PTEN
18 renal/urinary system MP:0005367 9.96 CASP8 EDNRB EGFR ERCC1 GDF15 IL4
19 no phenotypic analysis MP:0003012 9.95 CYP1A1 EGFR FADD IL4 PIK3CA SOX2
20 reproductive system MP:0005389 9.93 EGFR ERBB2 ERCC1 FADD IL4 MCL1
21 pigmentation MP:0001186 9.72 EDNRB EGFR PTEN SOD2 SOX2
22 respiratory system MP:0005388 9.61 CASP8 EDNRB EGFR ERBB2 IL4 PTEN
23 skeleton MP:0005390 9.36 EDNRB EGFR ERBB2 ERCC1 FADD IL4

Drugs & Therapeutics for Oral Cavity Cancer

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4 Autonomic Agents Phase 4
5 Neurotransmitter Agents Phase 4
6 Psychotropic Drugs Phase 4
7 Liver Extracts Phase 4
8 Central Nervous System Stimulants Phase 4
9 Cholinergic Agents Phase 4
10 Nicotinic Agonists Phase 4
11 Dopamine Agents Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Dopamine Uptake Inhibitors Phase 4
14 Antidepressive Agents Phase 4
15 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
16
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
17
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
20 Muscarinic Agonists Phase 2, Phase 3
21 Anti-Inflammatory Agents Phase 2, Phase 3
22 Gastrointestinal Agents Phase 2, Phase 3
23 Analgesics, Non-Narcotic Phase 2, Phase 3
24 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
25 Cyclooxygenase Inhibitors Phase 2, Phase 3
26 Analgesics Phase 2, Phase 3
27 Anti-Bacterial Agents Phase 2, Phase 3
28 Antiemetics Phase 2, Phase 3
29 HIV Protease Inhibitors Phase 2, Phase 3
30 Cyclooxygenase 2 Inhibitors Phase 2, Phase 3
31
protease inhibitors Phase 2, Phase 3
32 Angiogenesis Inhibitors Phase 2, Phase 3
33 BB 1101 Phase 2, Phase 3
34 glucocorticoids Phase 2, Phase 3
35 Anti-Infective Agents Phase 2, Phase 3
36 Antineoplastic Agents, Hormonal Phase 2, Phase 3
37 Hormone Antagonists Phase 2, Phase 3
38 Hormones Phase 2, Phase 3
39
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
40
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
41
Indinavir Approved Phase 2 150378-17-9 5362440
42
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
43
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
44
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
45
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
46
Hydroxyurea Approved Phase 2 127-07-1 3657
47
Zinc oxide Approved Phase 2 1314-13-2
48
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
49
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
50
Valproic acid Approved, Investigational Phase 2 99-66-1 3121

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
3 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
4 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
5 Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201279 Phase 3 13-cis Retino Acid
6 Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
7 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
8 Multicentre,A Phase II/III Randomized Study of Adjuvant Anti-Angiogenesis Therapy for Patients of High-Risk Oral Cavity Cancer Terminated NCT00934739 Phase 2, Phase 3 Thalidomide, Celebrex;Cyclophosphamide, Dexamethasone
9 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
10 Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Unknown status NCT03008694 Phase 2
11 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
12 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
13 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
14 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
15 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment Followed by 6 Weeks of Cetuximab+RT Post Surgery in Locally Advanced Squamous Cell Carcinoma of the Tongue ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
16 Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer Unknown status NCT02262221 Phase 2
17 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
18 A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804 Completed NCT01116843 Phase 1, Phase 2 PF-00299804
19 Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light Completed NCT00002964 Phase 2 porfimer sodium
20 Efficacy of Implant-Supported Maxillofacial Prostheses Completed NCT00006341 Phase 2
21 Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response Completed NCT01914900 Phase 2 docetaxel, cisplatin, 5 fluorouracil
22 Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
23 Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions Completed NCT00014404 Phase 2 celecoxib
24 Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Completed NCT01695122 Phase 2 Valproic Acid
25 A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
26 A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia Completed NCT00004161 Phase 2 fenretinide;Placebo
27 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
28 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
29 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
30 Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment Completed NCT00780312 Phase 2
31 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
32 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
33 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
34 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
35 A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation Completed NCT00534001 Phase 2 bupropion hydrochloride
36 Phase II Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Recruiting NCT03021993 Phase 2 Nivolumab
37 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02873819 Phase 2 GL-0817;Hiltonol;Sargramostim;cyclophosphamide;Placebo
38 A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting NCT03422536 Phase 2 Ficlatuzumab
39 A Phase II Study of Maintenance Tegafur-uracil in Patients With Squamous Cell Carcinoma of Oral Cavity With Extracapsular Spreading of Lymph Nodes Recruiting NCT03121313 Phase 2 tegafur-uracil
40 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
41 Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer Recruiting NCT03532737 Phase 2 Pembrolizumab
42 A Randomized Multicenter Phase II Study Using (2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a) (HPPH) With PDT Versus Standard of Care Surgery for Patients With T1/T2 N0 Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting NCT03090412 Phase 2 HPPH;Photodynamic Therapy
43 A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting NCT02609386 Phase 2 Cyclophosphamide;Indomethacin;Omeprazole
44 Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias Active, not recruiting NCT02882282 Phase 2
45 Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting NCT02919683 Phase 2 Nivolumab;Ipilimumab
46 A Phase II Open-label, Single Arm Study to Evaluate the Efficacy of Sintilimab(IBI 308) to Prevent High-risk Oral Premalignant Lesions Cancerization Not yet recruiting NCT04065737 Phase 2 Sintilimab
47 NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Not yet recruiting NCT03721757 Phase 2
48 Open Label Single Arm Phase Ib-II Study of Pre-operative IPH2201 in Patients With Locally Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity Terminated NCT02331875 Phase 1, Phase 2 IPH2201
49 A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia Terminated NCT00003223 Phase 2 fenretinide
50 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Head and Neck Terminated NCT00003489 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)

Search NIH Clinical Center for Oral Cavity Cancer

Genetic Tests for Oral Cavity Cancer

Anatomical Context for Oral Cavity Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

19
The

MalaCards organs/tissues related to Oral Cavity Cancer:

40
Lymph Node, Tongue, Breast, Lung, Neutrophil, Testes, Prostate

Publications for Oral Cavity Cancer

Articles related to Oral Cavity Cancer:

(show top 50) (show all 853)
# Title Authors PMID Year
1
Association between coffee intake and the risk of oral cavity cancer: a meta-analysis of observational studies. 61
31021885 2020
2
Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples. 61
31835136 2019
3
Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer. 61
31809562 2019
4
Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. 61
31837576 2019
5
Association between pioglitazone use and head and neck cancer: Population-based case-control study. 61
31833151 2019
6
Prevalence and incidence of oral cancer in low- and middle-income countries: A scoping review. 61
31820851 2019
7
Symptom burden among head and neck cancer patients in the first year after diagnosis: Association with primary treatment modality. 61
31630058 2019
8
Can Early Dental Extractions Reduce Delays in Postoperative Radiation for Patients With Advanced Oral Cavity Carcinoma? 61
31228426 2019
9
The oral cavity tumor thickness: Measurement accuracy and consequences for tumor staging. 61
31227341 2019
10
Role of Smoking-Mediated molecular events in the genesis of oral cancers. 61
31345084 2019
11
Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review. 61
31499275 2019
12
Sarcopenia Results in Poor Survival Rates in Oral Cavity Cancer Patients. 61
31769607 2019
13
Near-infrared fluorescence imaging improves the nodal yield in neck dissection in oral cavity cancer - A randomized study. 61
31307814 2019
14
What is the oncologic safety of using the submental flap to reconstruct oral cavity cancer defects? 61
31424567 2019
15
Lymph node yield, depth of invasion, and survival in node-negative oral cavity cancer. 61
31586894 2019
16
The profound oral cavity cancer burden in the United States Commonwealth of the Northern Mariana Islands: A global health opportunity. 61
31351740 2019
17
Postoperative wound infections, neutrophil-to-lymphocyte ratio, and cancer recurrence in patients with oral cavity cancer undergoing surgical resection. 61
31421467 2019
18
18F-FDG PET/CT versus CT/MR imaging for detection of neck lymph node metastasis in palpably node-negative oral cavity cancer. 61
31606761 2019
19
Social determinants of health and oral cavity cancer treatment and survival: A competing risk analysis. 61
31654440 2019
20
Early oral cavity cancer: The prognostic factors and impact of adjuvant radiation on survival. 61
31339609 2019
21
Relevant changes in the AJCC 8th edition staging manual for oral cavity cancer and future implications. 61
30943732 2019
22
Smokeless tobacco use and risk of oral cavity cancer. 61
31655504 2019
23
Tumor Depth of Invasion (Tumor > 4 cm/Depth > 10 mm and Depth > 20 mm) and Through Cortex/Skin Invasion are Both Valid Criteria for Classifying Tumors as pT4a in AJCC 2018 Oral Cavity Cancer Staging System. 61
31264118 2019
24
Delays in oral cavity cancer. 61
30878273 2019
25
Impact of physical and psychosocial dysfunction on return to work in survivors of oral cavity cancer. 61
31291694 2019
26
Time patterns of recurrence and second primary tumors in a large cohort of patients treated for oral cavity cancer. 61
31400079 2019
27
Validation of the Brandwein Gensler Risk Model in Patients of Oral Cavity Squamous Cell Carcinoma in North India. 61
31552620 2019
28
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. 61
31082494 2019
29
Analysis of Process-Related Quality Metrics and Survival of Patients with Oral Cavity Squamous Cell Carcinoma. 61
31060452 2019
30
Identification and characterization of novel human papillomaviruses in oral rinse samples from oral cavity and oropharyngeal cancer patients. 61
31129167 2019
31
Incidence trends for upper aerodigestive tract cancers in rural United States counties. 61
30843640 2019
32
Evaluation of early oral cavity cancer treatment quality at a single institution. 61
30408196 2019
33
The economic burden of oral squamous cell carcinoma in Australia. 61
31177557 2019
34
Oral Cavity Cancer in the Indian Subcontinent - Challenges and Opportunities. 61
31174947 2019
35
Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry. 61
31345385 2019
36
Does Clearance of Positive Margins Improve Local Control in Oral Cavity Cancer? A Meta-analysis. 61
30912991 2019
37
Prognostic determinants of locally advanced buccal mucosa cancer: Do we need to relook the current staging criteria? 61
31345393 2019
38
Functional and molecular effects of a green tea constituent on oral cancer cells. 61
31188490 2019
39
Extracapsular extension in oral cavity cancers-predictive factors and impact on recurrence pattern and survival. 61
31003838 2019
40
Cancer stem cell self-renewal as a therapeutic target in human oral cancer. 61
30936460 2019
41
Body Image Disturbance in Surgically Treated Head and Neck Cancer Patients: A Prospective Cohort Pilot Study. 61
30857488 2019
42
All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma. 61
30900104 2019
43
Tongue function and its influence on masticatory performance in patients treated for oral cancer: a five-year prospective study. 61
31273502 2019
44
Not CD68 but stabilin-1 expression is associated with the risk of recurrence in patients with oral cavity squamous cell carcinoma. 61
30652402 2019
45
Somatic Mitochondrial Mutations in Oral Cavity Cancers among Senegalese Patients. 61
31350985 2019
46
Relocation of inadequate resection margins in the wound bed during oral cavity oncological surgery: A feasibility study. 61
30706624 2019
47
Depth of invasion for prognostic stratification in oral cavity cancer: do we need further validation? 61
31576293 2019
48
Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. 61
31046104 2019
49
Effect of Hypofractionated, Palliative Radiotherapy on Quality of Life in Late-Stage Oral Cavity Cancer: A Prospective Clinical Trial. 61
31413453 2019
50
Increased risk of larynx cancer in patients with gastroesophageal reflux disease from a national sample cohort. 61
30884136 2019

Variations for Oral Cavity Cancer

ClinVar genetic disease variations for Oral Cavity Cancer:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
2 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
3 PIK3CA NM_006218.4(PIK3CA):c.3145G>C (p.Gly1049Arg)SNV Likely pathogenic 376053 rs121913277 3:178952090-178952090 3:179234302-179234302

Expression for Oral Cavity Cancer

Search GEO for disease gene expression data for Oral Cavity Cancer.

Pathways for Oral Cavity Cancer

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 VEGFA TLR6 TLR2 SOX2 PTEN PIK3CA
2
Show member pathways
13.77 VEGFA TNFRSF10B SOX2 PTEN IL4 GDF15
3
Show member pathways
13.34 VEGFA SOX2 PIK3CA MCL1 IL4 ERBB2
4
Show member pathways
13.31 TNFRSF10B TLR6 TLR2 PTEN IL4 GDF15
5
Show member pathways
13.29 TNFRSF10B PTEN IL4 GDF15 ERBB2 EGFR
6
Show member pathways
13.11 TLR6 TLR2 PIK3CA FADD EGFR CASP8
7
Show member pathways
12.91 VEGFA TLR2 PIK3CA FADD EGFR CASP8
8
Show member pathways
12.87 VEGFA TNFRSF10B PTEN PIK3CA FADD EGFR
9
Show member pathways
12.81 TNFRSF10B TLR2 PIK3CA FADD CASP8
10
Show member pathways
12.79 TNFRSF10B PIK3CA MCL1 FADD CASP8
11
Show member pathways
12.75 PTEN PIK3CA GSTM1 ERBB2 EGFR
12
Show member pathways
12.69 TLR6 TLR2 GDF15 FADD EGFR
13
Show member pathways
12.69 VEGFA TLR2 PTEN PIK3CA MCL1 IL4
14
Show member pathways
12.6 VEGFA PTEN PIK3CA ERBB2 EGFR
15
Show member pathways
12.58 TLR2 PTEN PIK3CA IL4 EGFR
16
Show member pathways
12.55 TNFRSF10B TLR6 TLR2 FADD CASP8
17 12.52 TNFRSF10B TLR6 TLR2 IL4 GDF15
18
Show member pathways
12.49 PIK3CA ERBB2 EGFR CASP8
19
Show member pathways
12.43 PIK3CA ERBB2 EGFR CASP8
20 12.4 VEGFA PTEN PIK3CA MCL1 ERBB2 EGFR
21
Show member pathways
12.36 VEGFA TLR6 TLR2 PIK3CA EGFR
22
Show member pathways
12.33 PIK3CA MCL1 IL4 EGFR
23
Show member pathways
12.32 TLR2 IL4 FADD CASP8
24
Show member pathways
12.28 TNFRSF10B PIK3CA FADD CASP8
25 12.23 VEGFA TLR2 PIK3CA ERBB2 EGFR
26 12.22 TLR6 TLR2 FADD CASP8
27 12.18 VEGFA TLR6 TLR2 EGFR
28 12.16 TNFRSF10B MCL1 GDF15 FADD CASP8
29
Show member pathways
12.11 PTEN PIK3CA ERBB2 EGFR
30
Show member pathways
12.08 PTEN PIK3CA ERBB2 EGFR
31 12.05 VEGFA PTEN PIK3CA IL4 GSTM1 FADD
32 12.04 VEGFA PTEN FADD EGFR CASP8
33
Show member pathways
11.94 SOD2 PTEN PIK3CA EGFR CAT
34 11.93 VEGFA SOX2 MCL1 IL4
35 11.9 VEGFA PIK3CA ERBB2 EGFR
36 11.89 TNFRSF10B PTEN MCL1 GDF15 EGFR
37
Show member pathways
11.83 TLR6 TLR2 PIK3CA ERBB2 EGFR CASP8
38
Show member pathways
11.8 MCL1 FADD CASP8
39 11.78 SOD2 PTEN PIK3CA ERBB2 CAT
40 11.73 VEGFA ERBB2 EGFR
41 11.67 PTEN PIK3CA ERBB2
42 11.62 PTEN PIK3CA ERBB2 EGFR
43 11.51 VEGFA EGFR CYP1A1
44 11.49 VEGFA PIK3CA CASP8
45 11.44 TNFRSF10B FADD CASP8
46
Show member pathways
11.42 VEGFA PIK3CA EGFR
47 11.3 PIK3CA GSTM1 FADD ERCC1 ERBB2 CASP8
48 11.25 SOD2 CYP1A1 CAT
49 11.24 PIK3CA ERBB2 EGFR

GO Terms for Oral Cavity Cancer

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.21 VEGFA TLR2 SOX2 PTEN PIK3CA MCL1
2 cell body GO:0044297 9.5 TLR2 FADD CASP8
3 death-inducing signaling complex GO:0031264 9.26 FADD CASP8
4 ripoptosome GO:0097342 9.16 FADD CASP8
5 membrane raft GO:0045121 9.1 TLR6 TLR2 FADD EGFR EDNRB CASP8
6 CD95 death-inducing signaling complex GO:0031265 8.96 FADD CASP8

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.11 TNFRSF10B TLR2 PTEN MCL1 FADD CASP8
2 signal transduction GO:0007165 10.07 VEGFA TNFRSF10B TLR6 TLR2 IL4 GDF15
3 cytokine-mediated signaling pathway GO:0019221 9.97 VEGFA SOX2 PIK3CA MCL1 IL4
4 cell proliferation GO:0008283 9.96 PTEN ERCC1 EGFR CYP1A1
5 aging GO:0007568 9.94 PTEN EDNRB CYP1A1 CAT
6 positive regulation of protein phosphorylation GO:0001934 9.93 VEGFA ERBB2 EGFR EDNRB
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.92 TNFRSF10B TLR6 FADD CASP8
8 regulation of apoptotic process GO:0042981 9.92 TNFRSF10B MCL1 GDF15 FADD CASP8
9 positive regulation of protein kinase B signaling GO:0051897 9.91 PIK3CA GDF15 ERBB2 EGFR
10 response to lipopolysaccharide GO:0032496 9.9 TLR2 EDNRB CYP1A1 CASP8
11 response to hypoxia GO:0001666 9.89 VEGFA TLR2 CYP1A1 CAT
12 positive regulation of gene expression GO:0010628 9.88 VEGFA TLR6 TLR2 PTEN IL4 ERBB2
13 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.86 TNFRSF10B FADD CASP8
14 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 VEGFA PIK3CA EGFR
15 liver development GO:0001889 9.84 PIK3CA EGFR CYP1A1
16 response to organic cyclic compound GO:0014070 9.84 PTEN EGFR EDNRB CYP1A1
17 cellular response to growth factor stimulus GO:0071363 9.83 ERBB2 EGFR CAT
18 positive regulation of epithelial cell proliferation GO:0050679 9.83 VEGFA ERBB2 EGFR
19 positive regulation of MAP kinase activity GO:0043406 9.82 VEGFA ERBB2 EGFR
20 response to estradiol GO:0032355 9.78 PTEN EGFR CAT CASP8
21 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.75 TNFRSF10B FADD CASP8
22 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.73 TNFRSF10B FADD CASP8
23 negative regulation of apoptotic process GO:0043066 9.7 VEGFA PTEN MCL1 IL4 EGFR EDNRB
24 ERBB2 signaling pathway GO:0038128 9.69 PIK3CA ERBB2 EGFR
25 regulation of cytokine secretion GO:0050707 9.68 TLR6 TLR2
26 toll-like receptor 3 signaling pathway GO:0034138 9.67 FADD CASP8
27 cell activation GO:0001775 9.67 TLR6 TLR2
28 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.67 TLR6 FADD CASP8
29 death-inducing signaling complex assembly GO:0071550 9.65 FADD CASP8
30 regulation of necroptotic process GO:0060544 9.64 FADD CASP8
31 negative regulation of ERBB signaling pathway GO:1901185 9.62 ERBB2 EGFR
32 cellular response to mechanical stimulus GO:0071260 9.62 TNFRSF10B FADD EGFR CASP8
33 cellular response to diacyl bacterial lipopeptide GO:0071726 9.61 TLR6 TLR2
34 toll-like receptor TLR6:TLR2 signaling pathway GO:0038124 9.58 TLR6 TLR2
35 nitric oxide metabolic process GO:0046209 9.55 TLR6 TLR2
36 detection of diacyl bacterial lipopeptide GO:0042496 9.46 TLR6 TLR2
37 response to bacterial lipoprotein GO:0032493 9.43 TLR6 TLR2
38 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.43 TNFRSF10B FADD CASP8
39 cell surface receptor signaling pathway GO:0007166 9.43 TNFRSF10B FADD ERBB2 EGFR EDNRB CASP8
40 TRAIL-activated apoptotic signaling pathway GO:0036462 8.8 TNFRSF10B FADD CASP8

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 VEGFA TNFRSF10B TLR6 TLR2 SOX2 PTEN
2 enzyme binding GO:0019899 9.72 PTEN GSTM1 EGFR CYP1A1 CAT
3 protein heterodimerization activity GO:0046982 9.43 VEGFA TLR6 TLR2 MCL1 ERBB2 EGFR
4 lipopeptide binding GO:0071723 9.37 TLR6 TLR2
5 identical protein binding GO:0042802 9.32 VEGFA TLR6 TLR2 SOD2 PTEN FADD
6 death effector domain binding GO:0035877 9.16 FADD CASP8

Sources for Oral Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....